Cargando…

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported. The potential interactions between atovaquone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tommasi, Chiara, Bellagamba, Rita, Tempestilli, Massimo, D'Avolio, Antonio, Gallo, Anna L, Ivanovic, Jelena, Nicastri, Emanuele, Pucillo, Leopoldo P, Narciso, Pasquale
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112458/ https://www.ncbi.nlm.nih.gov/pubmed/21600016 http://dx.doi.org/10.1186/1475-2875-10-141

Ejemplares similares

Atovaquone/proguanil‐induced autoimmune‐like hepatitis
por: Terziroli Beretta‐Piccoli, Benedetta, et al.
Publicado: (2017)

Assessment of acceptability and ease of use of atovaquone/proguanil medication in subjects undergoing malaria prophylaxis
por: Nicosia, V, et al.
Publicado: (2008)

Plasmodium falciparum Malaria and Atovaquone-Proguanil Treatment Failure
por: Durand, Rémy, et al.
Publicado: (2008)

Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria
por: Blanshard, Andrew, et al.
Publicado: (2021)

Tolerability of Atovaquone—Proguanil Application in Common Buzzard Nestlings
por: Wiegmann, Anja, et al.
Publicado: (2022)

A survey on outcomes of accidental atovaquone–proguanil exposure in pregnancy
por: Tan, Kathrine R., et al.
Publicado: (2018)

Cyclization-blocked proguanil as a strategy to improve the antimalarial activity of atovaquone
por: Skinner-Adams, Tina S., et al.
Publicado: (2019)

Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis
por: Staines, Henry M, et al.
Publicado: (2018)

Proguanil and atovaquone use is associated with lower colorectal cancer risk: a nationwide cohort study
por: Zhang, Naiqi, et al.
Publicado: (2022)

Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola
por: Pimentel, Sónia, et al.
Publicado: (2006)

Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa
por: Happi, Christian T, et al.
Publicado: (2006)

Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast
por: Wurtz, Nathalie, et al.
Publicado: (2012)

A Longitudinal Trial Comparing Chloroquine as Monotherapy or in Combination with Artesunate, Azithromycin or Atovaquone-Proguanil to Treat Malaria
por: Laufer, Miriam K., et al.
Publicado: (2012)

The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: modelling mass drug administration and treatment
por: Maude, Richard J, et al.
Publicado: (2014)

Atovaquone-proguanil in the treatment of imported uncomplicated Plasmodium falciparum malaria: a prospective observational study of 553 cases
por: Cordel, Hugues, et al.
Publicado: (2013)

Delayed Onset of Symptoms and Atovaquone-Proguanil Chemoprophylaxis Breakthrough by Plasmodium malariae in the Absence of Mutation at Codon 268 of pmcytb
por: Teo, Beatrix Huei-Yi, et al.
Publicado: (2015)

Unanticipated CNS Safety Signal in a Placebo‐Controlled, Randomized Trial of Co‐Administered Atovaquone‐Proguanil and Amodiaquine
por: Chalon, Stephan, et al.
Publicado: (2021)

Amplicon Deep Sequencing Reveals Multiple Genetic Events Lead to Treatment Failure with Atovaquone-Proguanil in Plasmodium falciparum
por: Castañeda-Mogollón, Daniel, et al.
Publicado: (2023)

In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand
por: Khositnithikul, Rommanee, et al.
Publicado: (2008)

Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil
por: Sutherland, Colin J, et al.
Publicado: (2008)

A Safe and Effective Atovaquone-Proguanil Therapeutic Protocol for the Treatment of Avian Malaria by Plasmodium relictum in Snowy Owl (Bubo scandiacus)
por: Pugliese, Nicola, et al.
Publicado: (2023)

Novel Mutation in Cytochrome B of Plasmodium falciparum in One of Two Atovaquone-Proguanil Treatment Failures in Travelers Returning From Same Site in Nigeria
por: Plucinski, Mateusz M., et al.
Publicado: (2014)

Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone–proguanil in traveller returning from Congo
por: Massamba, Laurencie, et al.
Publicado: (2020)

Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
por: Bakshi, Rahul P., et al.
Publicado: (2018)

1024. Evaluation of Atovaquone Prescribing for Pneumocystis jiroveci Pneumonia (PJP) Prophylaxis
por: Aleissa, Muneerah, et al.
Publicado: (2019)

Profile of etravirine for the treatment of HIV infection
por: Tseng, Alice, et al.
Publicado: (2010)

New-Onset Saquinavir-Induced Diabetes
por: van Zoelen, Marieke A.D., et al.
Publicado: (2013)

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
por: Mulligan, Nikki, et al.
Publicado: (2016)

Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine
por: Corpolongo, Angela, et al.
Publicado: (2012)

2696. Breakthrough Toxoplasmosis While on Atovaquone Prophylaxis Following Allogeneic Hematologic Stem Cell Transplantation
por: Chueng, Teresa A, et al.
Publicado: (2019)

Babesia microti Variant With Multiple Resistance Mutations Detected in an Immunocompromised Patient Receiving Atovaquone Prophylaxis
por: Holbrook, Nolan R, et al.
Publicado: (2023)

Tratamiento con saquinavir + zalcitabina + zidovudina vs saquinavir + lamivudina + zidovudina en pacientes con SIDA sin tratamiento previo
por: Jaimes Martínez, Marcos
Publicado: (2000)

Antimalarial pharmacology and therapeutics of atovaquone
por: Nixon, Gemma L., et al.
Publicado: (2013)

Pancytopenia due to proguanil toxicity in a returning traveller with fever
por: Jolink, Hetty, et al.
Publicado: (2010)

Paludrine (Proguanil) as a Suppressive and Prophylactic in P.-Vivax Infections
por: Desai, V. G.
Publicado: (1951)

Lausannevirus Encodes a Functional Dihydrofolate Reductase Susceptible to Proguanil
por: Mueller, L., et al.
Publicado: (2017)

Saquinavir: From HIV to COVID-19 and Cancer Treatment
por: Pereira, Mariana, et al.
Publicado: (2022)

Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates
por: van der Velden, Maarten, et al.
Publicado: (2017)

The role of etravirine in the management of treatment-experienced pediatric patients with HIV
por: Osterholzer, Danielle
Publicado: (2013)

Decreased Phenotypic Susceptibility to Etravirine in Patients with Predicted Genotypic Sensitivity
por: Agneskog, Eva, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_aabiiocu04va430jkaine7sko0